Contineum Therapeutics, Inc. Investment Income, Interest
Contineum Therapeutics, Inc. (CTNM) reported Investment Income, Interest of $2.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-07-30
- Contineum Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $2.34M, a 15.43% increase year-over-year.
- Contineum Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $2.50M, a 11.33% increase year-over-year.
- Contineum Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $2.01M, a 20.49% decline year-over-year.
- Contineum Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $1.96M, a 28.60% decline year-over-year.
- Contineum Therapeutics, Inc. investment income, interest for fiscal 2025 was $8.25M, a 7.40% decline from fiscal 2024.
- Contineum Therapeutics, Inc. investment income, interest for fiscal 2024 was $8.90M, a 93.33% increase from fiscal 2023.
- Contineum Therapeutics, Inc. investment income, interest for fiscal 2023 was $4.61M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.34M 10-Q · filed 2026-07-30 | $4.85M 10-Q · filed 2026-07-30 | $6.86M derived: sum of 3 quarters · filed 2026-07-30 | $8.81M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $2.50M 10-Q · filed 2026-05-05 | $4.51M derived: sum of 2 quarters · filed 2026-05-05 | $6.47M derived: sum of 3 quarters · filed 2026-05-05 | $8.50M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.97M derived: sum of 2 quarters · filed 2026-03-05 | $6.00M derived: sum of 3 quarters · filed 2026-07-30 | $8.25M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.96M 10-Q · filed 2025-10-30 | $3.99M derived: sum of 2 quarters · filed 2026-07-30 | $6.24M 10-Q · filed 2025-10-30 | $8.76M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $2.03M 10-Q · filed 2026-07-30 | $4.28M 10-Q · filed 2026-07-30 | $6.81M derived: sum of 3 quarters · filed 2026-07-30 | $9.55M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $2.25M 10-Q · filed 2026-05-05 | $4.78M derived: sum of 2 quarters · filed 2026-05-05 | $7.52M derived: sum of 3 quarters · filed 2026-05-05 | $9.52M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.27M derived: sum of 2 quarters · filed 2026-03-05 | $7.27M derived: sum of 3 quarters · filed 2026-03-05 | $8.90M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.74M 10-Q · filed 2025-10-30 | $4.74M derived: sum of 2 quarters · filed 2025-10-30 | $6.38M 10-Q · filed 2025-10-30 | $8.17M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $2.00M 10-Q · filed 2025-08-05 | $3.64M 10-Q · filed 2025-08-05 | $5.43M derived: sum of 3 quarters · filed 2025-08-05 | $7.16M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.64M 10-Q · filed 2025-05-14 | $3.43M derived: sum of 2 quarters · filed 2025-05-14 | $5.16M derived: sum of 3 quarters · filed 2025-05-14 | $5.84M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $3.53M derived: sum of 2 quarters · filed 2025-03-06 | $4.21M derived: sum of 3 quarters · filed 2025-03-06 | $4.61M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.74M 10-Q · filed 2024-11-06 | $2.42M derived: sum of 2 quarters · filed 2024-11-06 | $2.82M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $679.00K 10-Q · filed 2024-08-14 | $1.08M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $401.00K 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |